ATE444309T1 - Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper - Google Patents

Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper

Info

Publication number
ATE444309T1
ATE444309T1 AT01957479T AT01957479T ATE444309T1 AT E444309 T1 ATE444309 T1 AT E444309T1 AT 01957479 T AT01957479 T AT 01957479T AT 01957479 T AT01957479 T AT 01957479T AT E444309 T1 ATE444309 T1 AT E444309T1
Authority
AT
Austria
Prior art keywords
immunotherapy
myelocytic leukemia
antibodies
naked anti
cronic
Prior art date
Application number
AT01957479T
Other languages
English (en)
Inventor
David Goldenberg
Hans Hansen
Original Assignee
Immunomedics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Immunomedics Inc filed Critical Immunomedics Inc
Application granted granted Critical
Publication of ATE444309T1 publication Critical patent/ATE444309T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Hematology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Oncology (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
AT01957479T 2000-08-08 2001-08-08 Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper ATE444309T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US22369800P 2000-08-08 2000-08-08
PCT/US2001/024691 WO2002012347A1 (en) 2000-08-08 2001-08-08 Immunotherapy for chronic myelocytic leukemia

Publications (1)

Publication Number Publication Date
ATE444309T1 true ATE444309T1 (de) 2009-10-15

Family

ID=22837639

Family Applications (1)

Application Number Title Priority Date Filing Date
AT01957479T ATE444309T1 (de) 2000-08-08 2001-08-08 Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper

Country Status (10)

Country Link
US (2) US6759045B2 (de)
EP (1) EP1309627B1 (de)
JP (1) JP3888971B2 (de)
CN (1) CN1468259A (de)
AT (1) ATE444309T1 (de)
AU (1) AU7921701A (de)
CA (1) CA2418014C (de)
DE (1) DE60140063D1 (de)
DK (1) DK1309627T3 (de)
WO (1) WO2002012347A1 (de)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1176195B1 (de) 1999-04-09 2013-05-22 Kyowa Hakko Kirin Co., Ltd. Verfahren zur kontrolle der aktivität von immunologisch funktionellem molekül
US20040071726A1 (en) * 2000-09-12 2004-04-15 Chicz Roman M Peptide epitopes recognized by antigen specific cd4lymphocytes
US6946292B2 (en) 2000-10-06 2005-09-20 Kyowa Hakko Kogyo Co., Ltd. Cells producing antibody compositions with increased antibody dependent cytotoxic activity
US20030124127A1 (en) * 2001-12-06 2003-07-03 Lijun Yang Targeting leukemia cells
AU2003226141A1 (en) * 2002-03-27 2003-10-13 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Method for treating cancer in humans
US7541440B2 (en) * 2002-09-30 2009-06-02 Immunomedics, Inc. Chimeric, human and humanized anti-granulocyte antibodies and methods of use
CA2504611A1 (en) * 2002-11-06 2004-05-27 Wyeth Combination therapy for the treatment of acute leukemia and myelodysplastic syndrome
DK1578446T3 (en) 2002-11-07 2015-06-29 Immunogen Inc ANTI-CD33 ANTIBODIES AND PROCEDURES FOR TREATING ACUTE MYELOID LEUKEMIA BY USING IT
EP2322547A1 (de) * 2003-06-25 2011-05-18 Crucell Holland B.V. Myeloidzellen-spezifisches Lectin
US7939058B2 (en) 2003-07-03 2011-05-10 University Of Southern California Uses of IL-12 in hematopoiesis
EP1702625B1 (de) 2003-12-04 2010-11-03 Kyowa Hakko Kirin Co., Ltd. Einen genetisch modifizierten antikörper gegen chemokin-rezeptor-ccr4 enthaltendes medikament
EP1732650A4 (de) * 2004-03-27 2008-06-11 Univ Arizona Zusammensetzung und verfahren für die krebsbehandlung
WO2006050075A2 (en) * 2004-10-29 2006-05-11 Regents Of The University Of California Method of increasing efficacy of tumor cell killing using combinations of anti-neoplastic agents
US20060234959A1 (en) * 2005-04-14 2006-10-19 Advanced Photodynamic Technologies, Inc. Photodynamic therapy utilizing multiple duty cycle light modulation
US20060257317A1 (en) * 2005-05-04 2006-11-16 Duke University Combination therapy in the treatment of cancer
US9072797B2 (en) 2005-11-30 2015-07-07 Therapharm Gmbh Immunoconjugate for human CD66 for the treatment of multiple myeloma and other haematological malignancies
WO2008029271A2 (en) * 2006-02-27 2008-03-13 Gal Markel Ceacam based antibacterial agents
WO2007119808A1 (ja) * 2006-04-13 2007-10-25 Medical And Biological Laboratories Co., Ltd. 融合パートナー細胞
AU2007317333A1 (en) * 2006-11-02 2008-05-15 Seattle Genetics, Inc. Methods of treating neoplastic, autoimmune and inflammatory diseases
EP2478110B1 (de) 2009-09-16 2016-01-06 Immunomedics, Inc. Klasse-i-anti-cea-antikörper und verwendungen davon
US20130309223A1 (en) 2012-05-18 2013-11-21 Seattle Genetics, Inc. CD33 Antibodies And Use Of Same To Treat Cancer
KR101645905B1 (ko) 2012-10-12 2016-08-04 스피로즌 살 피롤로벤조디아제핀 및 그의 컨주게이트
JP6445519B2 (ja) 2013-03-13 2018-12-26 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ ピロロベンゾジアゼピン及びそのコンジュゲート
EP2968585B1 (de) 2013-03-13 2018-07-18 Medimmune Limited Pyrrolobenzodiazepine und konjugate davon
WO2014140862A2 (en) 2013-03-13 2014-09-18 Spirogen Sarl Pyrrolobenzodiazepines and conjugates thereof
WO2016037644A1 (en) 2014-09-10 2016-03-17 Medimmune Limited Pyrrolobenzodiazepines and conjugates thereof
WO2017160954A1 (en) 2016-03-15 2017-09-21 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with bcl-2 inhibitors
US11110179B2 (en) 2016-06-03 2021-09-07 Seagen Inc. Combination of CD33 antibody drug conjugates with chemotherapeutic agents
WO2017214433A1 (en) 2016-06-09 2017-12-14 Seattle Genetics, Inc. Combinations of pbd-based antibody drug conjugates with flt3 inhibitors
JP2019534882A (ja) 2016-10-11 2019-12-05 メドイミューン・リミテッドＭｅｄＩｍｍｕｎｅ Ｌｉｍｉｔｅｄ 免疫介在性療法薬を有する抗体−薬物コンジュゲート
JP2021524449A (ja) 2018-05-23 2021-09-13 アーデーセー セラピューティクス ソシエテ アノニム 分子アジュバント
US20230372528A1 (en) 2020-10-16 2023-11-23 University Of Georgia Research Foundation, Inc. Glycoconjugates
GB202102396D0 (en) 2021-02-19 2021-04-07 Adc Therapeutics Sa Molecular adjuvant
WO2022078524A2 (en) 2021-11-03 2022-04-21 Hangzhou Dac Biotech Co., Ltd. Specific conjugation of an antibody

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4904596A (en) * 1985-08-07 1990-02-27 Fred Hutchinson Cancer Research Center Hybridoma antibody (FH6) defining a human cancer-associated difucoganglioside
CA2309652C (en) * 1997-11-10 2013-01-29 Memorial Sloan-Kettering Cancer Center Process for producing arsenic trioxide formulations and methods for treating cancer using arsenic trioxide or melarsoprol
CA2279474C (en) 1998-07-31 2011-01-04 Stemcell Technologies Inc. Novel antibody composition for debulking blood and bone marrow samples from cml patients

Also Published As

Publication number Publication date
AU7921701A (en) 2002-02-18
CA2418014A1 (en) 2002-02-14
EP1309627A1 (de) 2003-05-14
US20020022031A1 (en) 2002-02-21
DK1309627T3 (da) 2009-12-21
JP2004505994A (ja) 2004-02-26
CA2418014C (en) 2014-01-21
US6759045B2 (en) 2004-07-06
JP3888971B2 (ja) 2007-03-07
DE60140063D1 (de) 2009-11-12
US7323168B2 (en) 2008-01-29
AU2001279217C1 (en) 2002-02-18
EP1309627B1 (de) 2009-09-30
US20040213796A1 (en) 2004-10-28
CN1468259A (zh) 2004-01-14
WO2002012347A1 (en) 2002-02-14

Similar Documents

Publication Publication Date Title
ATE444309T1 (de) Immuntherapie für kronische myelozytische leukämie mit nacktem anti-nca-90 antikörper
PL377726A1 (pl) Sposoby i kompozycje do indukowania apoptozy komórek nowotworowych
MA42999B1 (fr) Polythérapie contenant ivosidenib, cytarabine et daunorubicin ou idarubicin pour le traitement de la leucémie myéloïde aiguë
MX2021007350A (es) Terapia combinada de cd70 y venetoclax, un inhibidor de bcl-2, para tratar la leucemia mieloide aguda.
CL2007001624A1 (es) Uso de un anticuerpo que se une a dll4 para el tratamiento de tumor, cancer o trastorno de proliferacion celular.
CL2012000519A1 (es) Uso de un anticuerpo aislado o fragmento de enlace antígeno del mismo que comprende una región variable de cadena ligera y una de cadena pesada (sec nº38 y nº40) útil en el tratamiento y prevención de carcinoma de células escamosas en un mamífero (div. sol. 3615-07).
SG160412A1 (en) Anti-igfr1 antibody therapeutic combinations
HUP0300590A2 (hu) Peptidázzal hasítható, célzott antineoplasztikus szerek és terápiás alkalmazásuk
IL214325A (en) Antibody against cmet, a drug that includes and uses it
DK1187632T3 (da) Behandling med anti-ErbB2-antistoffer
FR2869231B1 (fr) Composition therapeutique contenant au moins un derive de la pyrrolobenzodiazepine et la fludarabine
AU9660801A (en) Compositions and methods for wt1 specific immunotherapy
EP2269656A3 (de) Ausgewählte antikörper und duramycin-peptide mit bindung an anionische phospholipide und aminophospholipide und ihre verwendung bei der behandlung von virusinfektionen und krebs
MA43000B1 (fr) Polythérapie pour le traitement de tumeurs malignes
TW200612988A (en) Adjuvant therapy with the use of anti-glypican 3 antibody
AR052774A1 (es) Inmunoterapia para trastornos autoinmunes
AR023616A1 (es) Preparaciones combinadas que comprenden derivados de antraciclina
BR0306820A (pt) Uso de inibidores cox-2 em combinação com agentes antivirais para o tratamento de infecções de papilomavìrus
CY1110329T1 (el) Πεγκυλιωμενη λιποσωμιακη δοξορουβικινη σε συνδυασμο με εκτεϊνασκιδινη 743
WO2008112129A3 (en) Treatment of carcinomas with a combination of egf-pathway and telomerase inhibitors
AU2001260880A1 (en) Pharmaceutical compounds for treating copd
MXPA02007899A (es) Citoquinas modificadas para utilizarse en terapia de cancer.
MX2009010269A (es) Metodos de tratamiento del cancer mediante administracion de combinaciones de interleucina-18 humana.
IL141550A0 (en) Methods and compositions for the prevention or treatment of cancer
WO2008066854A3 (en) Methods and compositions for inducing apoptosis in cancer cells

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties